Riley Kandel

Articles

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL

December 2nd 2025

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma

December 1st 2025

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC

November 28th 2025

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

Evolving Approaches With BTK Inhibition and Targeted Therapy Seek to Improve Outcomes in High-Risk MCL

November 26th 2025

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma

November 25th 2025

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

FDA Grants Orphan Drug Designation to OBI-902 in Cholangiocarcinoma

November 25th 2025

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

Dr Freedland on the Efficacy Results From the EMBARK Trial of Enzalutamide in Prostate Cancer

November 24th 2025

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

Mecbotamab Vedotin Shows Potential to Extend Survival in Treatment-Refractory Soft Tissue Sarcomas

November 20th 2025

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

Modified Daratumumab-Based Quadruplet Shows Feasibility in Older Multiple Myeloma

November 19th 2025

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

FDA Awards Orphan Drug Designation to ZEN-3694 for NUT Carcinoma

November 18th 2025

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management

November 14th 2025

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.